First Trimester Bleeding

Am Fam Physician. 2009 Jun 1;79(11):985-992.

  Patient information: See related handout on first trimester bleeding, written by the authors of this article.

This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME).

Vaginal bleeding in the first trimester occurs in about one fourth of pregnancies. About one half of those who bleed will miscarry. Guarded reassurance and watchful waiting are appropriate if fetal heart sounds are detected, if the patient is medically stable, and if there is no adnexal mass or clinical sign of intraperitoneal bleeding. Discriminatory criteria using transvaginal ultrasonography and beta subunit of human chorionic gonadotropin testing aid in distinguishing among the many conditions of first trimester bleeding. Possible causes of bleeding include subchorionic hemorrhage, embryonic demise, anembryonic pregnancy, incomplete abortion, ectopic pregnancy, and gestational trophoblastic disease. When beta subunit of human chorionic gonadotropin reaches levels of 1,500 to 2,000 mIU per mL (1,500 to 2,000 IU per L), a normal pregnancy should exhibit a gestational sac by transvaginal ultrasonography. When the gestational sac is greater than 10 mm in diameter, a yolk sac must be present. A live embryo must exhibit cardiac activity when the crown-rump length is greater than 5 mm. In a normal pregnancy, beta subunit of human chorionic gonadotropin levels increase by 80 percent every 48 hours. The absence of any normal discriminatory findings is consistent with early pregnancy failure, but does not distinguish between ectopic pregnancy and failed intrauterine pregnancy. The presence of an adnexal mass or free pelvic fluid represents ectopic pregnancy until proven otherwise. Medical management with misoprostol is highly effective for early intrauterine pregnancy failure with the exception of gestational trophoblastic disease, which must be surgically evacuated. Expectant treatment is effective for many patients with incomplete abortion. Medical management with methotrexate is highly effective for properly selected patients with ectopic pregnancy. Follow-up after early pregnancy loss should include attention to future pregnancy planning, contraception, and psychological aspects of care.

About one fourth of all pregnant women experience spotting or bleeding in the first several weeks of pregnancy, and one half of those who bleed will miscarry.1 Family physicians who are familiar with the normal progression of early pregnancy anatomy, sonographic findings, and beta subunit of human chorionic gonadotropin (β-hCG) values can make a definitive diagnosis and proceed with appropriate treatment.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Evidence does not support the routine use of antibiotics in all women with incomplete abortion.

A

5

A normal pregnancy should exhibit a gestational sac when beta subunit of human chorionic gonadotropin levels reach 1,500 to 2,000 mIU per mL (1,500 to 2,000 IU per L), a yolk sac when the gestational sac is greater than 10 mm in diameter, and cardiac activity when the embryonic crown-rump length is greater than 5 mm.

C

1

Because expectant and surgical management of miscarriage are equally effective, the patient's preference should play a dominant role in choosing a treatment.

C

16

When the patient has an incomplete abortion, nonsurgical treatments have a high likelihood of success; when the patient has an embryonic demise or anembryonic pregnancy, misoprostol (Cytotec) or surgical treatment is more effective than expectant treatment.

A

1315

Vaginal misoprostol is safer and more effective than oral misoprostol, with fewer gastrointestinal side effects.

A

13, 15

After a first trimester pregnancy loss, patients who are Rh negative should receive 50 mcg of anti D immune globulin.

C

27

Acknowledgment of grief, sympathy, and reassurance are useful techniques in counseling patients after miscarriage.

C

31


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Evidence does not support the routine use of antibiotics in all women with incomplete abortion.

A

5

A normal pregnancy should exhibit a gestational sac when beta subunit of human chorionic gonadotropin levels reach 1,500 to 2,000 mIU per mL (1,500 to 2,000 IU per L), a yolk sac when the gestational sac is greater than 10 mm in diameter, and cardiac activity when the embryonic crown-rump length is greater than 5 mm.

C

1

Because expectant and surgical management of miscarriage are equally effective, the patient's preference should play a dominant role in choosing a treatment.

C

16

When the patient has an incomplete abortion, nonsurgical treatments have a high likelihood of success; when the patient has an embryonic demise or anembryonic pregnancy, misoprostol (Cytotec) or surgical treatment is more effective than expectant treatment.

A

1315

Vaginal misoprostol is safer and more effective than oral misoprostol, with fewer gastrointestinal side effects.

A

13, 15

After a first trimester pregnancy loss, patients who are Rh negative should receive 50 mcg of anti D immune globulin.

C

27

Acknowledgment of grief, sympathy, and reassurance are useful techniques in counseling patients after miscarriage.

C

31


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Managing First Trimester Bleeding

By definition, bleeding before 20 weeks of gestation constitutes threatened abortion (Table 12,3), but the majority of such pregnancies progress normally. The pace of evaluation depends on the patient's history, signs, and symptoms. If known, the time since the patient's last normal menses may be used to estimate the gestational age. In stable patients, the physical examination includes documentation of the size and position of the uterus, auscultation of fetal heart sounds by Doppler (if it has been at least 10 to 11 weeks since last normal menses), and bimanual examination for masses and tenderness. Guarded reassurance and watchful waiting are appropriate if fetal heart sounds are detected with Doppler, if the patient is stable, and if there is no adnexal mass, significant tenderness, or clinical sign of intraperitoneal bleeding.

Table 1

Definition of Terms Applied to Early Pregnancy Loss

Term Definition

Anembryonic pregnancy

Presence of a gestational sac larger than 18 mm without evidence of embryonic tissues (yolk sac or embryo); this term is preferable to the older and less accurate term “blighted ovum”

Ectopic pregnancy

Pregnancy outside the uterine cavity (most commonly in the fallopian tube) but may occur in the broad ligament, ovary, cervix, or elsewhere in the abdomen

Embryonic demise

An embryo larger than 5 mm without cardiac activity; this replaces the term “missed abortion”

Gestational trophoblastic disease or hydatidiform mole

Complete mole: placental proliferation in the absence of a fetus; most have a 46, XX chromosomal composition; all derived from paternal source

Partial mole: molar placenta occurring with a fetus; most are genetically triploid (69, XXY)

Heterotopic pregnancy

Simultaneous intrauterine and ectopic pregnancy; risk factors include ovulation induction, in vitro fertilization, and gamete intrafallopian transfer

Recurrent pregnancy loss

More than two consecutive pregnancy losses; “habitual aborter” has also been used but is no longer appropriate

Spontaneous abortion

Spontaneous loss of a pregnancy before 20 weeks' gestation

Complete abortion

Complete passage of all products of conception

Incomplete abortion

Occurs when some, but not all, of the products of conception have passed

Inevitable abortion

Bleeding in the presence of a dilated cervix; indicates that passage of the conceptus is unavoidable

Septic abortion

Incomplete abortion associated with ascending infection of the endometrium, parametrium, adnexa, or peritoneum

Subchorionic hemorrhage

Sonographic finding of blood between the chorion and uterine wall, usually in the setting of vaginal bleeding

Threatened abortion

Bleeding before 20 weeks' gestation in the presence of an embryo with cardiac activity and closed cervix

Vanishing twin

A multifetal pregnancy is identified and one or more fetuses later disappear (occurs more often now that early ultrasonography is common); if early in pregnancy, the embryo is often reabsorbed; if later in pregnancy, it leads to a compressed or mummified fetus or amorphous material


Information from references 2 and 3.

Table 1   Definition of Terms Applied to Early Pregnancy Loss

View Table

Table 1

Definition of Terms Applied to Early Pregnancy Loss

Term Definition

Anembryonic pregnancy

Presence of a gestational sac larger than 18 mm without evidence of embryonic tissues (yolk sac or embryo); this term is preferable to the older and less accurate term “blighted ovum”

Ectopic pregnancy

Pregnancy outside the uterine cavity (most commonly in the fallopian tube) but may occur in the broad ligament, ovary, cervix, or elsewhere in the abdomen

Embryonic demise

An embryo larger than 5 mm without cardiac activity; this replaces the term “missed abortion”

Gestational trophoblastic disease or hydatidiform mole

Complete mole: placental proliferation in the absence of a fetus; most have a 46, XX chromosomal composition; all derived from paternal source

Partial mole: molar placenta occurring with a fetus; most are genetically triploid (69, XXY)

Heterotopic pregnancy

Simultaneous intrauterine and ectopic pregnancy; risk factors include ovulation induction, in vitro fertilization, and gamete intrafallopian transfer

Recurrent pregnancy loss

More than two consecutive pregnancy losses; “habitual aborter” has also been used but is no longer appropriate

Spontaneous abortion

Spontaneous loss of a pregnancy before 20 weeks' gestation

Complete abortion

Complete passage of all products of conception

Incomplete abortion

Occurs when some, but not all, of the products of conception have passed

Inevitable abortion

Bleeding in the presence of a dilated cervix; indicates that passage of the conceptus is unavoidable

Septic abortion

Incomplete abortion associated with ascending infection of the endometrium, parametrium, adnexa, or peritoneum

Subchorionic hemorrhage

Sonographic finding of blood between the chorion and uterine wall, usually in the setting of vaginal bleeding

Threatened abortion

Bleeding before 20 weeks' gestation in the presence of an embryo with cardiac activity and closed cervix

Vanishing twin

A multifetal pregnancy is identified and one or more fetuses later disappear (occurs more often now that early ultrasonography is common); if early in pregnancy, the embryo is often reabsorbed; if later in pregnancy, it leads to a compressed or mummified fetus or amorphous material


Information from references 2 and 3.

Adnexal tenderness and the presence of a mass may indicate ectopic pregnancy. Hypotension with other symptoms of hemoperitoneum (e.g., shoulder pain, absent bowel sounds, distended doughy abdomen) may point to ruptured ectopic pregnancy and prompt immediate hospitalization for evaluation.

Examination with a vaginal speculum may reveal nonobstetric causes of bleeding, such as cervicitis, vaginitis, cystitis, trauma, cervical cancer, or polyps; or nonvaginal causes of bleeding, such as hemorrhoids. Significant cervical dilation or visible products of conception are indicative of an inevitable abortion. Tissue may be removed by gentle traction with ring forceps, and may be examined for the presence of chorionic villi (Figure 1) or sent for pathologic examination. Chorionic villi are indicative of spontaneous abortion. Table 2 shows risk factors of spontaneous abortion.24

Figure 1.

Passed tissue can be examined for chorionic villi. If chorionic villi are present, the pregnancy was intrauterine, except in the rare heterotopic pregnancy.

View Large


Figure 1.

Passed tissue can be examined for chorionic villi. If chorionic villi are present, the pregnancy was intrauterine, except in the rare heterotopic pregnancy.


Figure 1.

Passed tissue can be examined for chorionic villi. If chorionic villi are present, the pregnancy was intrauterine, except in the rare heterotopic pregnancy.

Table 2

Risk Factors for Spontaneous Abortion and Ectopic Pregnancy

Spontaneous abortion

Endocrine (e.g., progesterone deficiency, thyroid disease, uncontrolled diabetes)

Genetic aneuploidy (accounts for about one half of spontaneous abortions)

Immunologic (e.g., antiphospholipid syndrome, lupus)

Infection (e.g., chlamydia, gonorrhea, herpes, listeria, mycoplasma, syphilis, toxoplasmosis, ureaplasma)

Occupational chemical exposure

Radiation exposure

Uterine (e.g., congenital anomalies)

Ectopic pregnancy

Current intrauterine device

History of ectopic pregnancy

History of in utero exposure to diethylstilbestrol

History of genital infection, including pelvic inflammatory disease, chlamydia, or gonorrhea

History of tubal surgery, including tubal ligation or reanastomosis of the tubes after tubal ligation

In vitro fertilization

Infertility

Smoking


Information from references 2 through 4.

Table 2   Risk Factors for Spontaneous Abortion and Ectopic Pregnancy

View Table

Table 2

Risk Factors for Spontaneous Abortion and Ectopic Pregnancy

Spontaneous abortion

Endocrine (e.g., progesterone deficiency, thyroid disease, uncontrolled diabetes)

Genetic aneuploidy (accounts for about one half of spontaneous abortions)

Immunologic (e.g., antiphospholipid syndrome, lupus)

Infection (e.g., chlamydia, gonorrhea, herpes, listeria, mycoplasma, syphilis, toxoplasmosis, ureaplasma)

Occupational chemical exposure

Radiation exposure

Uterine (e.g., congenital anomalies)

Ectopic pregnancy

Current intrauterine device

History of ectopic pregnancy

History of in utero exposure to diethylstilbestrol

History of genital infection, including pelvic inflammatory disease, chlamydia, or gonorrhea

History of tubal surgery, including tubal ligation or reanastomosis of the tubes after tubal ligation

In vitro fertilization

Infertility

Smoking


Information from references 2 through 4.

Cervical testing for gonorrhea and chlamydia may be performed. Fever and significant adnexal or peritoneal symptoms are found in septic abortion. Treatment of septic abortion is urgent, including prompt antibiotic administration and uterine evacuation. Infection, retained products of conception, and uterine perforation are more common if the history includes attempted abortion by someone who is untrained. Evidence does not support the routine use of antibiotics in all women with incomplete abortion.5

If history and physical examination do not yield a diagnosis, ultrasonography with or without β-hCG testing is required. Application and interpretation of this testing will help determine the differential diagnosis of early pregnancy failure.

Normal First Trimester Pregnancy Markers

HUMAN CHORIONIC GONADOTROPIN

The first measurable finding in pregnancy is an elevated β-hCG level, which is produced by the placenta after implantation of the blastocyst. This occurs at approximately 23 menstrual days' gestation, or as early as eight days after conception. Readily available home urine pregnancy tests detect β-hCG levels as low as 25 mIU per mL (25 IU per L) International Reference Preparation. Therefore, it is possible to diagnose pregnancy before a missed period.6

Quantitative serum β-hCG levels rise in a predictable fashion during the first four to eight weeks of normal pregnancy, increasing by 80 percent every 48 hours. This rate of increase in β-hCG levels is reassuring, but not indicative of normal pregnancy. Inadequately rising β-hCG levels do not distinguish between ectopic and failing intrauterine pregnancy. Unexpectedly high β-hCG levels require consideration of gestational trophoblastic disease.

ULTRASONOGRAPHY

Early detection of pregnancy depends on transvaginal ultrasonography using transducer frequency of 5 MHz or greater.1 A 5-mm sonolucent gestational sac should be visible in the endometrium at the fundus by five menstrual weeks.1 The normal sac of an intrauterine pregnancy consists of a central blastocyst surrounded by a double ring of echogenic chorionic villi and decidua. This distinguishes it from a pseudogestational sac associated with ectopic pregnancy.

The yolk sac is visible using transvaginal scanning by six menstrual weeks. This confirms an intrauterine pregnancy (Figure 2). By the end of the sixth week, a 2- to 5-mm embryo or fetal pole becomes visible (Figure 3). Measurement of the embryonic crown-rump length is the most accurate way to date pregnancy (Figure 4). Cardiac activity should be present when the embryo exceeds 5 mm in length.1 Transabdominal scanning is less sensitive, and will show these landmarks about one week after they are visible transvaginally.

Figure 2.

Yolk sac (YS) within the gestational sac at five to six menstrual weeks. This is the first sonographic finding that positively confirms intrauterine pregnancy.

View Large


Figure 2.

Yolk sac (YS) within the gestational sac at five to six menstrual weeks. This is the first sonographic finding that positively confirms intrauterine pregnancy.


Figure 2.

Yolk sac (YS) within the gestational sac at five to six menstrual weeks. This is the first sonographic finding that positively confirms intrauterine pregnancy.

Figure 3.

The embryo is first visible as a fetal pole adjacent to the yolk sac (YS). Cardiac activity is often visible at this time.

View Large


Figure 3.

The embryo is first visible as a fetal pole adjacent to the yolk sac (YS). Cardiac activity is often visible at this time.


Figure 3.

The embryo is first visible as a fetal pole adjacent to the yolk sac (YS). Cardiac activity is often visible at this time.

Figure 4.

Measurement of the embryonic crown-rump length is the most accurate way to date pregnancy. This 10.5-week pregnancy measures 38 mm.

View Large


Figure 4.

Measurement of the embryonic crown-rump length is the most accurate way to date pregnancy. This 10.5-week pregnancy measures 38 mm.


Figure 4.

Measurement of the embryonic crown-rump length is the most accurate way to date pregnancy. This 10.5-week pregnancy measures 38 mm.

DISCRIMINATORY CRITERIA

The predictable, linked progression of laboratory and sonographic findings constitutes discriminatory criteria, as shown in Table 3.1 A normal pregnancy should exhibit a gestational sac when β-hCG levels reach 1,500 to 2,000 mIU per mL (1,500 to 2,000 IU per L), a yolk sac when the gestational sac is greater than 10 mm in diameter, and cardiac activity when the crown-rump length is greater than 5 mm.1 The absence of an expected discriminatory finding is consistent with pregnancy failure; however, because of the emotional impact of pregnancy loss, imaging may be repeated one week later to confirm the diagnosis. After an embryo with a heartbeat is confirmed using these criteria, continued follow-up by ultrasonography provides more specific information about the state of the pregnancy than serial measurements of β-hCG.

Making a Diagnosis

If the diagnosis is not clear from clinical examination alone, knowledge of discriminatory criteria based on transvaginal ultrasonography and β-hCG findings facilitates the differential diagnosis of first trimester bleeding (Table 31).

Table 3

Discriminatory Findings in Early Pregnancy

Menstrual age Embryologic event Laboratory and transvaginal sonographic discriminatory findings

Three to four weeks

Implantation site

Decidual thickening

Four weeks

Trophoblast

Peritrophoblastic flow on color flow Doppler

Four to five weeks

Gestational sac

Present when beta subunit of human chorionic gonadotropin level is greater than 1,500 to 2,000 mIU per mL (1,500 to 2,000 IU per L; varies with sonographer experience and quality of ultrasonography)

Five to six weeks

Yolk sac

Present when diameter of gestational sac is greater than 10 mm

Five to six weeks

Embryo

Present when diameter of gestational sac is greater than 18 mm

Five to six weeks

Cardiac activity

Present when embryonic crown-rump length is greater than 5 mm


Adapted with permission from Paspulati RM, Bhatt S, Nour SG. Sonographic evaluation of first-trimester bleeding [published correction appears in Radiol Clin North Am. 2008;46(2):437]. Radiol Clin North Am. 2004;42(2):299. http://www.sciencedirect.com/science/journal/00338389.

Table 3   Discriminatory Findings in Early Pregnancy

View Table

Table 3

Discriminatory Findings in Early Pregnancy

Menstrual age Embryologic event Laboratory and transvaginal sonographic discriminatory findings

Three to four weeks

Implantation site

Decidual thickening

Four weeks

Trophoblast

Peritrophoblastic flow on color flow Doppler

Four to five weeks

Gestational sac

Present when beta subunit of human chorionic gonadotropin level is greater than 1,500 to 2,000 mIU per mL (1,500 to 2,000 IU per L; varies with sonographer experience and quality of ultrasonography)

Five to six weeks

Yolk sac

Present when diameter of gestational sac is greater than 10 mm

Five to six weeks

Embryo

Present when diameter of gestational sac is greater than 18 mm

Five to six weeks

Cardiac activity

Present when embryonic crown-rump length is greater than 5 mm


Adapted with permission from Paspulati RM, Bhatt S, Nour SG. Sonographic evaluation of first-trimester bleeding [published correction appears in Radiol Clin North Am. 2008;46(2):437]. Radiol Clin North Am. 2004;42(2):299. http://www.sciencedirect.com/science/journal/00338389.

ECTOPIC PREGNANCY

Ectopic pregnancy is responsible for 6 percent of all U.S. maternal deaths.4 Intrauterine pregnancy with yolk sac or embryo rules out ectopic pregnancy, with the exception of a one in 4,000 chance of heterotopic pregnancy. Transvaginal ultrasonography demonstrates an intra-uterine gestational sac with nearly 100 percent sensitivity at β-hCG levels of 1,500 to 2,000 mIU per mL.1 If the β-hCG level is above this discriminatory cutoff and a gestational sac is not visible, then there is a high likelihood of ectopic pregnancy.

An embryo with cardiac activity outside the uterus proves ectopic pregnancy. Conditions that impede the tubal transport of a fertilized ovum are associated with ectopic pregnancy7  (Table 224), although many ectopic pregnancies occur in women without risk factors. Early diagnosis is the key to preventing morbidity and mortality, and preserving fertility.

An adnexal mass or free pelvic fluid (Figure 5) signifies a high probability of ectopic pregnancy, even if the gestational sac or embryo is not visible. The presence of a corpus luteum cyst of pregnancy may confuse the picture.

Figure 5.

The presence of free pelvic fluid in the cul-de-sac is highly suggestive of ectopic pregnancy.

View Large


Figure 5.

The presence of free pelvic fluid in the cul-de-sac is highly suggestive of ectopic pregnancy.


Figure 5.

The presence of free pelvic fluid in the cul-de-sac is highly suggestive of ectopic pregnancy.

SPONTANEOUS ABORTION AND EMBRYONIC DEMISE

Products of conception in the cervix or an intrauterine embryo without cardiac activity proves incomplete abortion, inevitable abortion, or embryonic demise. Their presence rules out ectopic pregnancy, although there is a one in 4,000 chance of heterotopic pregnancy. Anembryonic pregnancy is often suspected when the patient reports regression of pregnancy symptoms or when Doppler fails to detect fetal heart sounds by 10 to 11 weeks after the last normal menses.

GESTATIONAL TROPHOBLASTIC DISEASE

Gestational trophoblastic disease is characterized by a “snowstorm” of amorphous material filling the uterus in patients presenting in the first trimester.8,9 Prompt surgical evacuation is required with close follow-up because of the risk of metastatic disease.9

SUBCHORIONIC HEMORRHAGE

Subchorionic hemorrhage (Figure 6) is a common finding with first trimester bleeding and may also be an incidental finding in uncomplicated pregnancies. It is important to note whether embryonic cardiac activity is present. Subchorionic hemorrhage may be mistaken for a twin gestational sac.

Figure 6.

Subchorionic hemorrhage (SCH) appears as a sonolucent area adjacent to the gestational sac, which contains an embryo (E) and yolk sac (YS).

View Large


Figure 6.

Subchorionic hemorrhage (SCH) appears as a sonolucent area adjacent to the gestational sac, which contains an embryo (E) and yolk sac (YS).


Figure 6.

Subchorionic hemorrhage (SCH) appears as a sonolucent area adjacent to the gestational sac, which contains an embryo (E) and yolk sac (YS).

THE DIFFICULT DIAGNOSIS

It is common for β-hCG levels to be less than 1,500 mIU per mL with sonographic findings that are nondiagnostic. It is reasonable to perform repeat ultrasonography after one week in a stable patient. This interval allows significant growth of the gestational sac or embryo, both of which should grow at the rate of 1 mm per day. In this situation, serial quantitative β-hCG levels in combination with follow-up imaging are also useful. Based on a prospective study, the minimum β-hCG increase necessary for a living pregnancy over a 48-hour interval is 53 percent.10 When β-hCG rises more slowly than this, plateaus, or falls, the differential diagnosis is limited to failing intrauterine pregnancy or ectopic pregnancy.

When β-hCG levels are not rising normally and ultrasonography cannot confirm pregnancy location, a dilatation and curettage or manual vacuum aspiration may be helpful. Manual vacuum aspiration requires a specially-designed 60-mL syringe with attached cannula to apply suction to the uterine cavity. If evacuation of the uterus yields chorionic villi, then a failed intrauterine pregnancy is diagnosed and treatment for an ectopic pregnancy may be avoided. When ectopic pregnancy is suspected but cannot be confirmed with noninvasive testing, consultation for diagnostic laparoscopy or treatment with methotrexate is appropriate.

Management

THREATENED ABORTION

The presence of an intrauterine embryo with cardiac activity on ultrasonography should be reassuring because it essentially rules out ectopic pregnancy. It is also associated with a pregnancy loss rate of only 2 percent in women 35 years and younger and 16 percent in women older than 35 years.11 If subchorionic hemorrhage (Figure 6) is present in an intrauterine pregnancy with fetal heart sounds, the likelihood of spontaneous abortion is 9 percent and may be even higher if the patient is older than 35 years or if the hematoma is large.12 In this situation, the physician should caution patients to expect continued bleeding and possible impending miscarriage.

SPONTANEOUS ABORTION, EMBRYONIC DEMISE, AND ANEMBRYONIC PREGNANCY

Most first trimester miscarriages occur completely and spontaneously without intervention. Although dilatation and curettage has historically been the treatment of choice, several recent trials confirm that expectant management or medical management with misoprostol (Cytotec) can be as effective and safer while offering the patient more control over her care.1316

Clinical trials comparing expectant, medical, and surgical management reach several conclusions. In incomplete abortion, high success rates have been demonstrated for expectant management (86 percent) and medical management (100 percent).13 However, expectant management is more likely to fail in embryonic demise or anembryonic pregnancy; in these patients, the success of expectant management by day 7 drops to 29 percent, compared with 87 percent for medical management.13 Women treated expectantly have more outpatient visits than those treated medically.13 Women treated medically have more bleeding but less pain than those treated surgically.14 Surgery is associated with more trauma and infectious complications than medical treatment.14,16 Misoprostol has fewer gastrointestinal side effects when given vaginally than when given orally.13,15

Based on these findings, increased use of medical management has benefits for patients, although misoprostol is not approved by the U.S. Food and Drug Administration for use in treating miscarriage.17 The doses used in published studies are 800 mcg vaginally or 600 mcg orally.13-15 If a single vaginal dose of 800 mcg does not result in complete expulsion by day 3, the dose should be repeated. If complete expulsion has not occurred by day 8, manual vacuum aspiration should be offered.18 Additional published protocols are available.19

Confirming a negative urine β-hCG four to six weeks after early pregnancy loss excludes the presence of persistent gestational trophoblastic disease.20 Although there is solid evidence to support the use of prophylactic antibiotics for induced abortion, there is no evidence supporting this practice in early pregnancy failure.21

ECTOPIC PREGNANCY

Early diagnosis of ectopic pregnancy brings management into the outpatient setting. Current treatment options favor medical and laparoscopic management,22 with expectant management reserved for patients with a declining quantitative β-hCG of less than 1,000 mIU per mL (1,000 IU per L) and open surgical management reserved for patients with tubal rupture and hemoperitoneum. Medical management with methotrexate is appropriate for properly selected patients. Randomized trials have shown medical management to be safer, more effective, and less expensive than conservative surgical treatment, and to result in equal or better subsequent fertility.23-26  Ectopic pregnancy management options, including methotrexate dosages and follow-up criteria, are shown in Table 4.2326

Table 4

Criteria for Managing Ectopic Pregnancy

Expectant management

No evidence of tubal rupture

Minimal pain or bleeding

Patient reliable for follow-up

Starting β-hCG level less than 1,000 mIU per mL (1,000 IU per L) and falling

Ectopic or adnexal mass less than 3 cm or not detected

No embryonic heartbeat

Medical management with methotrexate

Stable vital signs and few symptoms

No medical contraindication for methotrexate therapy (e.g., normal liver enzymes, complete blood count and platelet count)

Unruptured ectopic pregnancy

Absence of embryonic cardiac activity

Ectopic mass of 3.5 cm or less

Starting β-hCG levels less than 5,000 mIU per mL (5,000 IU per L)

Dosage: single intramuscular dose of 1 mg per kg, or 50 mg per m2

Follow-up: β-hCG on the fourth and seventh posttreatment days, then weekly until undetectable, which usually takes several weeks

Expected β-hCG changes: initial slight increase, then 15 percent decrease between days 4 and 7; if not, repeat dosage or move to surgery

Special consideration: prompt availability of surgery if patient does not respond to treatment

Surgical management

Unstable vital signs or signs of hemoperitoneum

Uncertain diagnosis

Advanced ectopic pregnancy (e.g., high β-hCG levels, large mass, cardiac activity)

Patient unreliable for follow-up

Contraindications to observation or methotrexate


β- hCG = beta subunit of human chorionic gonadotropin.

Information from references 23 through 26.

Table 4   Criteria for Managing Ectopic Pregnancy

View Table

Table 4

Criteria for Managing Ectopic Pregnancy

Expectant management

No evidence of tubal rupture

Minimal pain or bleeding

Patient reliable for follow-up

Starting β-hCG level less than 1,000 mIU per mL (1,000 IU per L) and falling

Ectopic or adnexal mass less than 3 cm or not detected

No embryonic heartbeat

Medical management with methotrexate

Stable vital signs and few symptoms

No medical contraindication for methotrexate therapy (e.g., normal liver enzymes, complete blood count and platelet count)

Unruptured ectopic pregnancy

Absence of embryonic cardiac activity

Ectopic mass of 3.5 cm or less

Starting β-hCG levels less than 5,000 mIU per mL (5,000 IU per L)

Dosage: single intramuscular dose of 1 mg per kg, or 50 mg per m2

Follow-up: β-hCG on the fourth and seventh posttreatment days, then weekly until undetectable, which usually takes several weeks

Expected β-hCG changes: initial slight increase, then 15 percent decrease between days 4 and 7; if not, repeat dosage or move to surgery

Special consideration: prompt availability of surgery if patient does not respond to treatment

Surgical management

Unstable vital signs or signs of hemoperitoneum

Uncertain diagnosis

Advanced ectopic pregnancy (e.g., high β-hCG levels, large mass, cardiac activity)

Patient unreliable for follow-up

Contraindications to observation or methotrexate


β- hCG = beta subunit of human chorionic gonadotropin.

Information from references 23 through 26.

Care After Pregnancy Loss

Several follow-up issues must be addressed after any type of pregnancy loss. Women who are Rh negative and miscarry during the first trimester should receive 50 mcg of anti D immune globulin.27 Contraception should be discussed and started immediately. All methods are equally safe immediately following spontaneous abortion or ectopic pregnancy. There is no good evidence suggesting an ideal interpregnancy interval,28 but folic acid supplementation before attempts at future conception substantially reduces the risk of neural tube defects.29 The psychological impact of pregnancy loss can be devastating to the patient and her partner.30  Approaches to managing patient grief are shown in Table 5.31

Table 5

Approaches to Grief Counseling After Miscarriage

Acknowledge and attempt to dispel guilt

Acknowledge and legitimize grief

Provide comfort, sympathy, and ongoing support

Reassure the patient about the future

Counsel the patient on how to tell family and friends about the miscarriage:

Speak simply and honestly

Avoid medical details

Recognize that others may react emotionally

Explain how others can help, if known

Warn patients of the anniversary phenomenon

Include the patient's partner in your psychological care

Assess level of grief and adjust counseling accordingly


Information from reference 31.

Table 5   Approaches to Grief Counseling After Miscarriage

View Table

Table 5

Approaches to Grief Counseling After Miscarriage

Acknowledge and attempt to dispel guilt

Acknowledge and legitimize grief

Provide comfort, sympathy, and ongoing support

Reassure the patient about the future

Counsel the patient on how to tell family and friends about the miscarriage:

Speak simply and honestly

Avoid medical details

Recognize that others may react emotionally

Explain how others can help, if known

Warn patients of the anniversary phenomenon

Include the patient's partner in your psychological care

Assess level of grief and adjust counseling accordingly


Information from reference 31.

The Authors

MARK DEUTCHMAN, MD, is a professor in the Department of Family Medicine at the University of Colorado Denver School of Medicine in Aurora, Colorado. He received his medical degree from The Ohio State University in Columbus, and completed a family medicine residency at Sacred Heart Medical Center in Spokane, Wash.

AMY TANNER TUBAY, MD, is an adjunct instructor in the Department of Family and Preventive Medicine at the University of Utah School of Medicine in Salt Lake City. She received her medical degree from Emory University School of Medicine in Atlanta, Ga., and completed a family medicine residency and an obstetrics fellowship at the University of Utah.

DAVID K. TUROK, MD, MPH, is an assistant professor in the Department of Obstetrics and Gynecology and the Department of Family and Preventive Medicine at the University of Utah School of Medicine. He received his medical and master of public health degrees from Tufts University in Boston, Mass., and completed a family medicine residency at Brown University in Pawtucket, R.I., and a residency in obstetrics and gynecology at the University of Utah School of Medicine.

Address correspondence to Mark Deutchman, MD, University of Colorado Denver School of Medicine, Mail Stop F-496, Academic Office 1, 12631 East 17th Ave., Room 3617, Aurora, CO 80045 (e-mail: mark.deutchman@ucdenver.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.


Figure 5 provided by Matthew F. Reeves, MD, MPH, Magee-Womens Hospital of the University of Pittsburgh (Pa.) Medical Center.

REFERENCES

1. Paspulati RM, Bhatt S, Nour SG. Sonographic evaluation of first-trimester bleeding [published correction appears in Radiol Clin North Am. 2008;46(2):437] Radiol Clin North Am. 2004;42(2):297–314http://www.sciencedirect.com/science/journal/00338389.

2. Creinin MD, Schwartz JL, Guido RS, Pymar HC. Early pregnancy failure–current management concepts. Obstet Gynecol Surv. 2001;56(2):105–113.

3. Chen BA, Creinin MD. Contemporary management of early pregnancy failure. Clin Obstet Gynecol. 2007;50(1):67–88.

4. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991–1997. Obstet Gynecol. 2003;101(2):289–296.

5. May W, Gülmezoglu AM, Ba-Thike K. Antibiotics for incomplete abortion. Cochrane Database Syst Rev. 2007;(4):CD001779.

6. Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. ACOG. Committee opinion: number 278, November 2002. Avoiding inappropriate clinical decisions based on false-positive human chorionic gonadotropin test results. Obstet Gynecol. 2002;100(5 pt 1):1057–1059.

7. Tay JI, Moore J, Walker JJ. Ectopic pregnancy [published correction appears in BMJ. 2000;321(7258):424]. BMJ. 2000;320(7239):916–919.

8. Dogra V, Paspulati RM, Bhatt S. First trimester bleeding evaluation. Ultrasound Q. 2005;21(2):69–85.

9. Committee on Practice Bulletins–Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol. 2004;103(6):1365–1377.

10. Barnhart KT, Sammel MD, Rinaudo PF, Zhou L, Hummel AC, Guo W. Symptomatic patients with an early viable intrauterine pregnancy; HCG curves redefined. Obstet Gynecol. 2004;104(1):50–55.

11. Smith KE, Buyalos RP. The profound impact of patient age on pregnancy outcome after early detection of fetal cardiac activity. Fertil Steril. 1996;65(1):35–40.

12. Bennett GL, Bromley B, Lieberman E, Benacerraf BR. Subchorionic hemorrhage in first-trimester pregnancies: prediction of pregnancy outcome with sonography. Radiology. 1996;200(3):803–806.

13. Bagratee JS, Khullar V, Regan L, Moodley J, Kagoro H. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod. 2004;19(2):266–271.

14. Weeks A, Alia G, Blum J, et al. A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. Obstet Gynecol. 2005;106(3):540–547.

15. Zhang J, Giles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM, for the National Institute of Child Health and Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005;353(8):761–769.

16. Nanda K, Peloggia A, Grimes D, Lopez L, Nanda G. Expectant care versus surgical treatment for miscarriage. Cochrane Database Syst Rev. 2006;(2):CD003518.

17. Winikoff B. Pregnancy failure and misoprostol–time for a change. N Engl J Med. 2005;353(8):834–836.

18. Robledo C, Zhang J, Troendle J, et al. Clinical indicators for success of misoprostol treatment after early pregnancy failure. Int J Gynaecol Obstet. 2007;99(1):46–51.

19. Reproductive Health Access Project. Protocol of medical treatment of missed or incomplete abortion with misoprostol. http://www.reproductiveaccess.org/m_m/protocol.htm. Accessed January 23, 2009.

20. Seckl MJ, Gillmore R, Foskett M, Sebire NJ, Rees H, Newlands ES. Routine terminations of pregnancy–should we screen for gestational trophoblastic neoplasia? Lancet. 2004;364(9435):705–707.

21. Prieto JA, Eriksen NL, Blanco JD. A randomized trial of prophylactic doxycycline for curettage in incomplete abortion. Obstet Gynecol. 1995;85(5 pt 1):692–696.

22. Hajenius PJ, Mol F, Mol BW, Bossuyt PM, Ankum WM, van der Veen F. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev. 2007;(1):CD000324.

23. Cohen MA, Sauer MV. Expectant management of ectopic pregnancy. Clin Obstet Gynecol. 1999;42(1):48–54.

24. ACOG practice bulletin. Medical management of tubal pregnancy. Number 3, December 1998. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1999;65(1):97–103.

25. Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol. 1993;168(6 pt 1):1759–1762.

26. Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med. 1999;341(26):1974–1978.

27. ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1999;66(1):63–70.

28. Vlaanderen W, Fabriek LM, van Tuyll van Serooskerken C. Abortion risk and pregnancy interval. Acta Obstet Gynecol Scand. 1988;67(2):139–140.

29. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev. 2001;(3):CD001056.

30. Deutchman M, Eisinger S, Kelber M. First trimester pregnancy complications. In: ALSO: Advanced Life Support in Obstetrics course syllabus. 4th ed. Leawood, Kan.: American Academy of Family Physicians; 2000:1–27.

31. DeFrain J, MilIspaugh E, Xie X. The psychosocial effects of miscarriage: implications for health professionals. Fam Syst Health. 1996;14(3):331–347.

This article is one in a series on “Advanced Life Support in Obstetrics (ALSO),” initially established by Mark Deutchman, MD, Denver, Colo. The series is now coordinated by Patricia Fontaine, MD, MS, ALSO Managing Editor, Minneapolis, Minn., and Larry Leeman, MD, MPH, ALSO Associate Editor, Albuquerque, N.M.


Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article